07 March 2008 - MacoPharma announces that after the second Marketing Authorisation of the THERAFLEX Methylene Blue (MB)-Plasma in Germany by the Paul-Ehrlich-Institute (PEI) to the Blood Centre of the German Red Cross chapters of NSTOB/ Springe, also SwissMedic, the responsible authority for marketing approval in Switzerland and also the Austrian Drug Surveillance Institute (ARGES) have given their principal agreement to use this procedure for virus inactivation of single units of therapeutic human plasma... MacoPharma's Press Release -Blog Archive
-
►
2008
(66)
-
►
September
(7)
- About GENOMIC VISION
- Magnisense : MIAplex, a unique magnetic technology...
- MAT Biopharma : completion of enrollment for Ferri...
- CERENIS THERAPEUTICS : PHASE I CLINICAL TRIAL OF C...
- Biomnis : Laboratory Pathology Handbook
- MEDIAN Technologies : contract in Barcelona
- Guerbet : Updated information about NSF and Dotar...
-
►
April
(10)
- Hybrigenics : Significant progress in cancer-relat...
- GENFIT : encouraging results in GFT505 first clini...
- Diatos : Pre-Clinical Results in Clinical Cancer R...
- BioAlliance Pharma Expands Its Loramyc Franchise
- PerkinElmer and Cerep : Partners for Custom Drug D...
- bioMerieux : Collaboration with University of Sun...
- GenOdyssee : Notice of Allowance from U.S. Patent ...
- LDR : Two-Level Cervical Disc Study Enrollment in ...
- MacoPharma : THERAFLEX Methylene Blue (MB)-Plasma
- genOway : Master service agreement with Boehringer...
-
►
March
(8)
- ExonHit : EHT 0202 Counters Scopolamine's Detrimen...
- Mauna Kea Technologies, a leader in in-vivo cellul...
- IMSTAR : point mutation detection on DNA microarra...
- Fovea Pharmaceuticals : Orphan Drug Designation fr...
- Air Liquide, First anesthesia with LENOXe
- Sanofi Pasteur , FDA Licenses DAPTACEL® Vaccine fo...
- TcLand Expression : creation of CIMNA, a unique in...
- Polyplus-transfection, GMP-quality clinical batch ...
-
►
September
(7)
Friday, April 4, 2008
MacoPharma : THERAFLEX Methylene Blue (MB)-Plasma
07 March 2008 - MacoPharma announces that after the second Marketing Authorisation of the THERAFLEX Methylene Blue (MB)-Plasma in Germany by the Paul-Ehrlich-Institute (PEI) to the Blood Centre of the German Red Cross chapters of NSTOB/ Springe, also SwissMedic, the responsible authority for marketing approval in Switzerland and also the Austrian Drug Surveillance Institute (ARGES) have given their principal agreement to use this procedure for virus inactivation of single units of therapeutic human plasma... MacoPharma's Press Release -